Hirokazu Nagai
Nagoya, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 185 publications
Hybrid Supercharged Antibodies: A Rational Approach to Boost Immunoassay Sensitivity via Controlled Nanoparticle Adsorption.
Journal: Langmuir : the ACS journal of surfaces and colloids
Published: April 03, 2026
Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.
Journal: Blood advances
Published: February 04, 2026
Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB.
Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Published: December 18, 2025
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
Journal: The Lancet. Haematology
Published: September 18, 2025
Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER).
Journal: Japanese journal of clinical oncology
Published: September 08, 2025
Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: June 01, 2025
Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma.
Journal: Japanese journal of clinical oncology
Published: May 07, 2025
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.
Journal: International journal of clinical oncology
Published: March 13, 2025
Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study).
Journal: Japanese journal of clinical oncology
Published: January 02, 2025
Last Updated: 09/26/2026